New PET Probes: A new way to streamline the IND process for FDA approval - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
New PET Probes: A new way to streamline the IND process for FDA approval


New PET Probes: A new way to streamline the IND process for FDA approval

PR Newswire

LOS ANGELES, June 4, 2014 /PRNewswire-USNewswire/ -- A recent article published in Molecular Imaging and Biology, the journal of the World Molecular Imaging Society, discusses a streamlined and cost-effective approach to obtain Investigational New Drug (IND) approvals from the Food and Drug Administration (FDA) for positron emission tomography (PET) imaging probes.  The article "de-mystifies" the process and provides a straightforward description on how to achieve approval for an imaging trial.

Using PET probes developed at UCLA, the Department of Molecular and Medical Pharmacology demonstrated the approach that can successfully be applied to obtain FDA approval of phase1 INDs in an academic site efficiently and at a reasonable cost.

"The low percentage transition of probes to investigations in humans can be attributed in part to the perception that complex regulatory requirements at high cost are associated with filing for an IND. We believe the information we have provided in our article presents a simpler, low cost approach for allowing more academic sites to transition their promising PET probes to the clinic" notes the author, Dr. Sherly Mosessian.

Dr. Michael Phelps states, "Our goal at UCLA is to apply university resources wherever appropriate to do our part to simplify, lower costs and increase quality in technologies and processes to expand the diversity of PET molecular imaging diagnostics to accommodate more diagnostic decisions in more diseases - both for developing better treatments and better use of existing ones to improve patient outcomes."

According to the study it is critical for academic sites to have a streamlined and cost-effective approach to translate PET imaging probes from preclinical research to clinical investigations and investigate the degree to which preclinical findings for these probes apply to humans.

ABOUT WORLD MOLECULAR IMAGING SOCIETY
The WMIS is dedicated to developing and promoting translational research through multimodal molecular imaging. The education and abstract-driven WMIC annual meeting is held in conjunction with European Society for Molecular Imaging (ESMI) and Federation of Asian Societies for Molecular Imaging (FASMI). WMIC provides a unique platform for scientists and clinicians with very diverse backgrounds to interact, present, and follow cutting-edge advances in molecular imaging.  Industry exhibits at the congress include the latest advances in preclinical and clinical imaging applications creating a complete molecular imaging educational technology showcase.

For more information: www.wmis.org

CONTACT: CHRISTIAAN KOOP
PHONE: 929-251-3429
E-MAIL: CKOOP@WMIS.ORG

SOURCE World Molecular Imaging Society

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here